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A B S T R A C T
In the period between October 1st and November 30th, 2006, we investigated a total of 3188 episodes of UTI (802
among males; 2386 among females) recorded in 108 family medicine offices in 20 cities in Croatia. The most common
UTIs in women were acute uncomplicated cystitis (62%), complicated UTIs – cystitis and pyelonephritis (14%), urethritis
(9%), acute uncomplicated pyelonephritis (6%), recurrent cystitis (5%), asymptomatic bacteriuria (3%) and recurrent
pyelonephritis. The most common UTIs in men were complicated UTIs – cystitis and pyelonephritis (48%), urethritis
(25%), prostatitis (24%) and asymptomatic bacteriuria (3%). Etiological diagnosis was made in 999 (31%) UTI episodes
before antimicrobial therapy was given. The most frequently isolated causative pathogens were Escherichia coli (77%),
Enterococcus faecalis (9%), Proteus mirabilis (5%), Klebsiella spp (3%), Streptococcus agalactiae (3%) and Enterobacter
(1%). Antimicrobial drug was administered in 2939 (92.19%) UTI episodes, in 1940 (66.01%) as empirical therapy, and
in 999 (34%) as targeted antimicrobial therapy. The most commonly administered drug in empirical therapy for acute
uncomplicated cystitis, recurrent cystitis and urethritis in women was cephalexin, for acute uncomplicated pyelonephri-
tis and complicated UTIs in women co-amoxiclav, and for UTIs in males ciprofloxacin. The results of this research of
3188 UTI episodes in family medicine physicians' offices provide a confirmatory answer to question whether empirical
antimicrobial therapy of UTI prescribed by Croatian family practitioners is in accordance with the national guidelines.
Key words: urinary tract infections, epidemiology, etiology, clinical presentation, treatment, family medicine practi-
tioners
Introduction
Urinary tract infections (UTI) comprise a heteroge-
neous group of clinical syndromes and diseases. Except
for location they differ in epidemiology, etiology, severity
of disturbed general condition and general symptoms of
infection, expressed local symptoms, frequency of recur-
rence and relapse, presence of complicating factors, nec-
essary antimicrobial therapy, outcome and prognosis.
UTI are among the most common bacterial infections in
humans and one of the most common reasons for pre-
scribing antimicrobial drugs1.
Research of UTIs in family medicine practitioners' of-
fices are rare, therefore the aim of this prospective re-
search was to investigate the epidemiology, etiology, clini-
cal presentation, complicating factors of UTIs treated by
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family physicinas and present the treatment of choice for
empirical antimicrobial therapy of UTI used in family
medicine offices in Croatia.
Patients and Methods
In the period from October 1st, 2006 until November
30th, 2006, a total of 108 family medicine offices in the
following cities in Croatia – Buzet, Drni{, Gospi}, Karlo-
vac, Ka{tel Su}urac, Kri`, Labin, Novska, Ogulin, Plo~e,
Posedarje, Pula, Rijeka, Sesvete, Split, Umag, Vi{kovo,
Vrsar, Zagreb, Zapre{i} – participated in a prospective re-
search of 3188 episodes of urinary tract infections (eUTI).
Each particular episode was attributed to one patient;
therefore the number of eUTI corresponded to the total
number of patients.
Diagnostic criteria of clinical syndromes
Urethritis – clinical syndrome characterized by ure-
thral inflammation and the following symptoms: dysu-
ria, polakisuria, mucopurulent or purulent discharge, or
urethral pruritis.
Acute uncomplicated cystitis – sporadic episode of
cystitis in premenopausal, non pregnant women with
clinical symptoms of dysuria, urgency, frequency, supra-
pubic pain, no fever, symptoms lasting less than 7 days,
no urinary symptoms 4 weeks prior current episode.
Urine culture should not be performed in young women.
The diagnosis should be based on characteristic symp-
toms and leukocyturia (positive leukocyte esterase test
or 10 WBC/mm3) ± positive nitrite test.
Acute uncomplicated pyelonephritis – sporadic epi-
sode of acute inflammation of kidney in women with sig-
nificant bacteriuria with 104 cfu/mL uropathogens in
midstream urine (MSU) and leukocyturia. Clinical symp-
toms are fever (>38°C), chills, flank pain, other diagnosis
excluded, no history of clinical evidence of urological ab-
normalities (ultrasonography, radiography).
Complicated UTI – including cystitis and pyelone-
phritis are UTI with any combination of symptoms from
cystitis or pyelonephritis and one or more factors associ-
ated with a complicated UTI. Laboratory criteria are
leukocyturia and significant bacteriuria 105 cfu/mL uro-
pathogens in women, 104 cfu/mL in men, and 103
cfu/mL in pregnant women.
Factors that suggest a potential complicated UTI are:
male sex, pregnancy, hospital acquired infection, the
presence of an indwelling catheter, stent or splint or the
use of intermittent bladder catheterization, vesicoure-
teric reflux or other functional or anatomical abnormali-
ties of the urinary tract, renal insufficiency, recent uri-
nary tract intervention (in the last 15 days), recent
antibiotic use (in the last 2–3 months), symptoms for >7
days at presentation, diabetes mellitus, immunosuppre-
ssion or immunocompromised diseases.
Asymptomatc bacteriuria – is a significant bacteriuria
and leukocyturia in a patient with no urinary symptoms.
Significant bacteriuria for asymptomatic bacteriuria in
females is 105 cfu/mL of the same bacterial strain in two
consecutive MSU cultures 24 hours apart; in males 105
cfu/mL in a single MSU culture.
Recurrent UTI – are at least three episodes of uncom-
plicated infection documented by culture in the last 12
months or two episodes in the last 6 months, only in
women with no structural/functional abnormalities. Lab-
oratory criteria are leukocyturia and significant bac-
teriuria of 103 cfu/mL for uncomplicated cystitis or 104
cfu/mL for uncomplicated pyelonephritis.
Prostatitis – clinical entity manifested with urethral
and urinary bladder symptoms (dysuria, polakisuria, ur-
gency, nocturia, weaker and intermittent urine flow, ure-
thral discharge), prostatic symptoms (pressure and pain
in perineal and groin areas, discomfort in the low back
and abdomen, tension in suprapubic, penile and scrotal
areas, epididymis, anorectal sensitivity), sexual distur-
bances (difficult and painful erection, loss of libido),
other symptoms (myalgia, headache, a low grade fever).
Methods
The following data were obtained for each patient: de-
mographic data, medical history, clinical status including
digitorectal prostatic examination when necessary and
medical documentation analysis. Data was collected ac-
cording to a specially designed questionnaire at the time
of the patient's arival to family medicine office and were
later on updated. This questionnaire proved suitable for
another pilot research2. Before study initiation, family
physicians were explained the aim of research, question-
naire and definitions necessary for filling it out.
Statistics
Data analysis was preformed by using Microsoft Ex-
cel/SAS, descriptive statistics and Mann-Whitney test.
Results
A total of 802 (25%) episodes were recorded among
males and 2386 (75%) among females. Median age was
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Fig. 1. Age and sex of patients with urinary tract infections ex-
amined at the family medicine physician's offices. Range min.
10.2 max. 99.4, Median age 52.8±18.8, n= 3188, F – 2386 (75%),
M – 802 (25%).
52.8±18.8 years, ranging from 10.2 to 99.4 years. There
was no statistically significant difference recorded be-
tween age in males and females with UTI (Figure 1).
The most common UTIs in women were acute uncom-
plicated cystitis (62%), complicated UTIs – cystitis and
pyelonephritis (14%), urethritis (9%), acute uncompli-
cated pyelonephritis (6%), recurrent cystitis (5%), asym-
ptomatic bacteriuria (3%) and recurrent pyelonephritis
(1%).
The most common UTIs in men were complicated
UTIs – cystitis and pyelonephritis (48%), urethritis (25%),
prostatitis (24%) and asymptomatic bacteriuria (3%)
(Table 1).
Complicating factors of UTI are shown in Table 2.
An average number of complicating factors, except
male sex, per eUTI in men with either cystitis or pyelo-
nephritis was 1.95; in men with prostatitis, except for
male sex 1.49; and in women with either cystitis or
pyelonephritis 1.49.
Acute uncomplicated cystitis in women occurred in all
age groups, more frequently in women over 40 years of
age, with altogether 65% of episodes of acute uncompli-
cated cystitis recorded in the age group 40–79 years.
Episodes of complicated UTIs in women were equally
distributed in all age groups from 18–79 years. In men,
the presence of complicating factors was more frequently
recorded in those older than 40 years of age.
Urethritis was common in age group 18–79 years in
both sexes and most common in age group 40–69 years
(male 56%, female 54%).
Altogether 68% of prostatitis episodes were recorded
in the age group 50–79.
Acute uncomplicated pyelonephritis was frequent among
women aged 50–79 years (57%).
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TABLE 1




n % n % n %
Acute uncomplicated cystitis – – 1479 (61.99) 1479 46.39
Recurrent cystitis – – 125 (5.24) 125 3.92
Acute uncomplicated pyelonephritis – – 134 (5.62) 134 4.20
Recurrent pyelonephritis – – 23 (0.96) 23 0.72
Complicated UTI 385 (48) 337 (14.12) 722 22.65
Urethritis 201 (25.06) 218 (9.14) 419 13.14
Prostatitis 192 (23.94) – – 192 6.02
Asymptomatic bacteriuria 24 (2.99) 70 (2.93) 94 2.95
TABLE 2
COMPLICATING FACTORS OF URINARY TRACT INFECTIONS RECORDED IN FAMILY MEDICINE PHYSICIAN'S OFFICES
Complicating factor







Symptoms > 7 days 239 36 129 404
Diabetes mellitus 152 14 105 271
Urolithiasis 101 21 74 196
Antibiotic therapy in the past 3 months 83 51 46 180
History of pyelonephritis 34 5 65 104
Functional or anatomical abnormality of the urinary tract 33 20 18 71
Immunosuppression 52 2 5 59
Pregnancy – – 41 41
Urinary catheter 34 – 2 36
Surgical procedure on urogenital tract 17 5 2 24
Incontinence – – 23 23
Hospital acquired UTI 7 5 3 15
Total 752 159 513 1424
Altogether 54% of recurrent cystitis episodes were
recorded among age group 60–79 years.
Etiological diagnosis was made in 999 (31%) UTI epi-
sodes before antimicrobial therapy were given (Table 3).
The most frequently isolated causative pathogens were
Escherichia coli (77%), Enterococcus faecalis (9%), Proteus
mirabilis (5%), Klebsiella spp (3%), Streptococcus agala-
ctiae (3%) and Enterobacter (1%).
Out of 3188 analyzed eUTI, at the time of research,
antimicrobial therapy was administered in 2939 (92.19%)
episodes. Empirical antimicrobial therapy was applied
in 1940 (66.01%) eUTI, and target antimicrobial ther-
apy in 999 (33.99%) (Table 4).
The most commonly administered drug in empirical
therapy for acute uncomplicated cystitis, recurrent cys-
titis and urethritis in women was cephalexin, for acute
uncomplicated pyelonephritis and complicated UTIs in
women co-amoxiclav, and for UTIs in males ciproflo-
xacin (Table 5). Altogether 151 (14.98%) female patient
with acute uncomplicated cystitis received nitrofurantoin,
and 36 (30.51%) men with urethritis doxycycline.
Discussion
The results of this research of 3188 UTI episodes in
family medicine physicians' offices have shown that in
practice, empirical antimicrobial therapy has to be used
very often for the treatment of UTIs. The aim of UTI
treatment is the disappearance of clinical symptoms and
eradication of infection in order to prevent relapse. All
symptomatic UTI and asymptomatic bacteriuria in cer-
tain individuals need to be treated. Antimicrobial spec-
trum of administered drug has to cover a range of de-
tected or expected causative pathogens and as least as
possible disturb normal human flora. Least toxic and at
the same time the cheapest medication should be admin-
istered in adequate dosage and for a sufficient long period
of time in order to eradicate infection. Empirical antimi-
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TABLE 3



























Escherichia coli 265 240 72 22 32 70 53 14 768 76.88
Enterococcus faecalis 11 50 5 7 – 2 17 – 92 9.21
Proteus mirabilis 16 9 5 11 2 – 5 2 50 5.0
Klebsiella spp 7 12 – 2 2 – 8 2 33 3.30
Streptococcus
agalactiae 6 5 4 – – 2 9 – 26 2.6
Enterobacter 4 5 2 1 – – – – 12 1.2
Staphylococcus
saprophyticus 4 – – – – – 1 – 5 0.5
Pseudomonas aer 1 3 – – – – – – 4 0.4
Staphylococcus
aureus 1 – 3 – – – – – 4 0.4
Serratia marcescens – 2 – – – – 1 – 3 0.3
Ureaplasma
urealyticum – – 1 1 – – – – 2 0.2
Total 315 326 92 44 36 74 94 18 999 100
Total episodes UTI 1479 722 419 192 134 125 94 23 3188
TABLE 4




Not treated at the time of research 249 (7.81%)
Etiologically confirmed (targeted therapy) 999 (33.99% of the total number of treated)
Empirical therapy 1940 (66.01% of the total number of treated)
crobial therapy is determined on the basis of local data
on the most common pathogens causing most frequent
clinical syndromes and their susceptibility to most com-
monly administered antimicrobial drugs.
Whenever possible, before starting antimicrobial
therapy, midstream urine for urine culture should be
collected. First morning sample or urine sample after
four hours of non urination should be collected. Urine
should be cultured within two hours from collection, if
not, than urine sample should be stored at +4°C up to
24 hours.
Empirical therapy should be modified according to
antibiogram as soon as urine culture results are available
– antibiotic therapy should be switched to antibiotic with
the narrowest spectrum and most effective against the
causative pathogen.
Since 1997, the resistance of bacterial pathogens to
antibiotics, in the most common clinical syndromes, has
been regularly monitored in Croatia. In the last five
years, we recorded no significant changes in the suscepti-
bility of E. coli to the most commonly administered
antimicrobial drugs (Table 6).
Local antibiotic resistance data were obtained from
the Committee for Antibiotic Resistance Surveillance of
the Croatian Academy of Medical Sciences3–7.
Croatian national guidelines for antimicrobial treat-
ment and prophylaxis of UTI were published in 20048.
With the help of the Croatian Ministry for Health and
Social Welfare, the Dutch Government and international
consultants, they were updated and via Internet and a
two-month-piloting period, widely presented to general
practitioners and specialists in urology, gynecology, infec-
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TABLE 5
EMPIRICAL ANTIMICROBIAL THERAPY OF 1490 UTI EPISODES RECORDED IN FAMILY MEDICINE PHYSICIANS' OFFICES
UTI episodes
Patients / Empirical therapy
Cephalexin Co-amoxiclav Ciprofloxacin Other Total
n % n % n % n % n %
Acute uncomplicated cystitis 818 79.57 16 1.56 – 194 18.87 1028 100
Acute uncomplicated pyelonephritis 2 1.6 95 76 12 9.6 16 12.8 125 100
Recurrent cystitis 51 85 7 11.67 2 3.33 – 60 100
Recurrent pyelonephritis 3 15 15 75 2 10 – 20 100
Complicated UTI
males 15 8.29 32 17.68 124 68.51 10 5.52 181 100
females 45 22.17 114 56.16 34 16.75 10 4.93 203 100
Urethritis
males 18 15.25 21 17.8 38 32.30 41 34.75 118 100
females 48 60 2 2.5 2 2.5 28 35 80 100
Prostatitis 10 8 15 12 88 70.4 12 9.6 125 100
Total 1110 317 302 211 1940
TABLE 6
THE RESISTANCE OF E. COLI TO THE MOST COMMON ANTIBIOTICS IN CROATIA IN THE PERIOD FROM 2002–2006
Antibiotic
Resistant (intermediate) %
2002 2003 2004 2005 2006
Nitrofurantoin 4 (1) 3 (1) 3 (1) 3 (1) 2 (1)
Trimethoprim-sulfamethoxazole 25 (0) 22 (0) 25 (0) 24 (1) 24 (0)
Amoxicillin 47 (1) 47 (1) 44 (1) 49 (1) 52 (1)
Cephalexin 11 (5) 9 (4) 9 (6) 11 (8) 8 (5)
Co-amoxiclav 8 (4) 6 (4) 5 (3) 5 (4) 4 (4)
Cefuroxim 5 (1) 3 (1) 3 (1) 3 (2) 2 (2)
Ceftibuten 3 (0) 2 (0) 2 (0) 1 (0) 2 (0)
Ceftriaxone 3 (0) 2 (0) 2 (0) 1 (0) 2 (0)
Gentamicin 7 (1) 5 (0) 5 (0) 6 (0) 6 (0)
Norfloxacin 8 (0) 8 (0) 7 (0) 10 (0) 10 (1)
Ciprofloxacin 7 (0) 8 (0) 7 (0) 10 (0) 10 (1)
tious diseases and nephrology working in primary health
care and hospitals9. The evidence for these guidelines
was based on a systemic review of the literature, local an-
tibiotic resistance data and local and international guide-
lines for the treatment of UTI10–17. Recommendations for
empirical antimicrobial therapy of UTI in family medi-
cine physicians' offices are shown in Table 78,9,18.
The results of this research of 3188 UTI episodes in
family medicine physicians' offices suggest that empirical
antimicrobial therapy of UTI prescribed by Croatian
family practitioners is in accordance with the national
guidelines.
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TABLE 7
CROATIAN RECOMMENDATIONS FOR EMPIRICAL ANTIMICROBIAL THERAPY OF UTI IN FAMILY MEDICINE PHYSICIANS' OFFICES
Empirical antimicrobial therapy*
Category of UTI First choice Alternative choice




Acute uncomplicated pyelonephritis co-amoxiclav/ 10–14 days
II and II generation cephalosporins/ 10–14 days
ciprofloxacin/ 7–10 days
Complicated UTI co-amoxiclav/ 10–14 days
II and II generation cephalosporins/ 10–14 days
ciprofloxacin/ 7–10 days
UTI in males with systemic symptoms ciprofloxacin/ 14 days
co-amoxiclav/ 14 days
II and II generation cephalosporins/ 14 days
UTI in males with systemic symptoms
and symptoms of prostatitis ciprofloxacin/ 4 weeks
co-amoxiclav/ 4 weeks
II and II generation cephalosporins/ 4 weeks
Asymptomatic bacteriuria no empiric therapy – treatment according to antibiogram for 3–7 days
Recurrent UTI the same as sporadic episodes except that previous isolates and their sensitivitypatterns should be taken into account
*doses are stated for an average adult body weight and normal kidney function
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ISTRA@IVANJE INFEKCIJA MOKRA]NOG SUSTAVA U ORDINACIJAMA LIJE^NIKA OBITELJSKE
MEDICINE – EMPIRIJSKA ANTIMIKROBNA TERAPIJA INFEKCIJA MOKRA]NOG SUSTAVA –
HRVATSKA ISKUSTVA
S A @ E T A K
U razdoblju od 1. listopada do 30. studenog 2006. godine istra`ili smo ukupno 3188 epizoda infekcija mokra}nog
sustava (IMS) (802 u mu{karaca; 2386 u `ena) zabilje`enih u 108 ordinacija lije~nika obiteljske medicine u 20 gradova u
Hrvatskoj. Naj~e{}e IMS u `ena bile su: akutni nekomplicirani cistitis (62%), komplicirane IMS – cistitis i pijelonefritis
(14%), uretritis (9%), akutni nekomplicirani pijelonefritis (6%), rekurentni cistitis (5%), asimptomatska bakteriurija
(3%) i rekurentni pijelonefritis. Naj~e{}e IMS u mu{karaca su bile komplicirane IMS – cistitis i pijelonefritis (48%),
uretritis (25%), prostatitis (24%) i asimptomatska bakteriurija (3%). Etiolo{ka dijagnoza postavljena je u 999 (31%)
epizoda IMS prije zapo~ete antimikrobne terapije. Naj~e{}i izolirani uzro~nici bili su Escherichia coli (77%), Entero-
coccus faecalis (9%), Proteus mirabilis (5%), Klebsiella spp (3%), Streptococcus agalactiae (3%) i Enterobacter (1%).
Antimikrobna terapija primijenjena je u 2939 (92.19%) epizoda IMS, u 1940 (66.01%) kao empirijska, a u 999 (34%) kao
ciljana antimikrobna terapija. Naj~e{}e primjenjivani lijek u empirijskoj terapiji akutnog nekompliciranog cistitisa,
rekurentnog cistitisa i uretritisa u `ena bio je cefaleksin, za lije~enje akutnog nekompliciranog pijelonefritisa i kompli-
cirane IMS u `ena koamoksiklav, a za IMS u mu{karaca ciprofloksacin. Rezultati ovog istra`ivanja 3188 epizoda IMS u
ordinacijama lije~nika obiteljske medicine daju potvrdan odgovor na pitanje o podudarnosti propisane empirijske anti-
mikrobne terapije IMS s nacionalnim preporukama.
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